VERTEX PHARMACEUTICALS INCVRTX
| Dec 31,
2010 | Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net (loss) income | -755 | 41 | -51 | -445 | -739 | -556 | -84 | 263 | 2,097 | 1,177 | 2,712 | 2,342 | 3,322 | 3,620 | -536 |
|---|
| Stock-based compensation expense | 91 | 118 | 114 | 127 | 178 | 231 | 238 | 291 | 325 | 360 | 429 | 441 | 491 | 581 | 699 |
|---|
| Depreciation and amortization expenses | 30 | 35 | 38 | 48 | 63 | 62 | 61 | 61 | 72 | 107 | 110 | 126 | 148 | 181 | 207 |
|---|
| Deferred income taxes | - | -8 | 37 | -285 | 0 | 3 | 17 | -121 | -1,512 | 167 | 277 | -155 | -276 | -536 | -349 |
|---|
| Losses on equity securities | - | - | - | - | - | - | - | - | - | 198 | 312 | 17 | -149 | -1 | -58 |
|---|
| Decrease in fair value of contingent consideration | - | - | - | - | - | - | - | - | - | 4 | 13 | -3 | -57 | -52 | -0 |
|---|
| Other non-cash items, net | - | -0 | 0 | -7 | - | -10 | -6 | 3 | -12 | -17 | -79 | -14 | -12 | -8 | 56 |
|---|
| Accounts receivable, net | 3 | 171 | -40 | -53 | -7 | 105 | 33 | 72 | 108 | 226 | 223 | 275 | 359 | 84 | 99 |
|---|
| Inventories | - | 111 | 30 | -7 | 16 | 23 | 16 | 45 | 32 | 64 | 132 | 93 | 136 | 323 | 517 |
|---|
| Prepaid expenses and other assets | 1 | 2 | 12 | 12 | 16 | 9 | 9 | 111 | -17 | -35 | 298 | 92 | 326 | 546 | 200 |
|---|
| Accounts payable | -1 | 37 | 15 | -49 | 25 | -2 | -12 | 9 | 37 | -23 | 51 | 32 | 121 | 49 | 50 |
|---|
| Accrued expenses | - | 117 | 29 | 44 | -3 | 103 | 89 | 246 | 196 | - | - | 305 | 543 | 429 | 213 |
|---|
| Other liabilities | - | - | - | - | - | - | - | - | - | 38 | 425 | 17 | 499 | 209 | 40 |
|---|
| Net cash (used in) provided by operating activities | -635 | - | 268 | -52 | -513 | -365 | 236 | 845 | 1,270 | 1,569 | 3,254 | 2,644 | 4,130 | 3,537 | -493 |
|---|
| Purchases of available-for-sale debt securities | - | - | - | - | - | - | - | - | - | 537 | 431 | 528 | 693 | 3,787 | 7,438 |
|---|
| Sales and maturities of available-for-sale debt securities | 1,285 | 1,016 | 1,368 | 2,348 | 1,558 | 1,067 | 758 | 369 | 432 | 476 | 372 | - | 920 | 839 | 4,466 |
|---|
| Purchases of property and equipment | 38 | 35 | 71 | 51 | 51 | 45 | 57 | 99 | 96 | 75 | 260 | 235 | 205 | 200 | 298 |
|---|
| Sale of equity securities | - | - | - | - | - | - | - | - | - | - | - | - | - | 95 | - |
|---|
| Net payments related to finite-lived intangible assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 188 |
|---|
| Acquisition of available-for-sale debt securities from Alpine Immune Sciences, Inc. | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 258 |
|---|
| Payment to acquire ViaCyte, Inc., net of cash acquired | - | - | - | - | - | - | - | - | - | 1,154 | - | - | 296 | - | - |
|---|
| Other investing activities | 1 | 0 | 1 | -2 | 0 | -0 | 0 | -0 | -0 | - | - | - | - | - | 54 |
|---|
| Net cash used in investing activities | 7 | - | - | - | - | - | - | -438 | -202 | -1,235 | 99 | -341 | -321 | -3,142 | -3,770 |
|---|
| Issuances of common stock under benefit plans | 33 | 125 | 192 | 266 | 275 | 186 | 68 | 345 | 289 | 343 | 265 | 102 | 186 | 135 | 115 |
|---|
| Repurchases of common stock | - | - | - | - | - | - | - | - | 350 | 192 | 539 | 1,425 | - | 428 | 1,177 |
|---|
| Payments in connection with common stock withheld for employee tax obligations | - | - | - | - | - | - | - | - | - | - | 200 | 136 | 172 | 226 | 405 |
|---|
| Payments on finance leases | - | - | - | - | - | - | - | - | - | 39 | 42 | 47 | 86 | 45 | 34 |
|---|
| Other financing activities | - | - | -19 | -68 | -60 | - | - | - | -0 | -2 | -2 | 6 | 4 | - | 6 |
|---|
| Net cash used in financing activities | 425 | - | - | - | - | - | - | 68 | -71 | 127 | -505 | -1,478 | -68 | -562 | -1,495 |
|---|
| Effect of changes in exchange rates on cash | - | - | - | - | - | - | - | - | - | 2 | 21 | -13 | -29 | 27 | -43 |
|---|
| Net (decrease) increase in cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | - | 991 | 462 | 2,868 | 811 | 3,712 | -140 | -5,800 |
|---|
| Income Taxes Paid, Net | - | - | 9 | 3 | 1 | 2 | -3 | 6 | 12 | 25 | 192 | 476 | 1,058 | 1,677 | 1,082 |
|---|
| Cash paid for interest | - | - | - | - | - | - | - | - | 66 | 56 | 55 | 56 | 52 | 43 | 31 |
|---|
| Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 180 | - |
|---|